Europe’s Ad Hoc Pandemic Response Highlights Supply Chain Weaknesses
More Collaboration, More Data, More Production The Way Forward?
Executive Summary
Panelists at a recent virtual session of the DIA’s Europe 2020 conference identified the positive and negative aspects of Europe’s response to the pandemic, and suggested ways of avoiding shortages and making the supply chain more resilient in the event of future crises.
You may also be interested in...
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.